Table 1.
Characteristics of systemic lupus erythematosus patients.
| Mean (±SD) | |
|---|---|
| N = | 52 |
| Age | 48 (±13.19) |
| Gender—Female (%) | 50 (96.2%) |
| BMI | 27 (±4.96) |
| Smoker, n (%) | 9 (17.3%) |
| Taking immunosuppresants, n (%) | 7 (13.5%) |
| Taking steroids, n (%) | 12 (23.1%) |
| Anti-DsDNA antibody iu/mL | 23.2 (±42.7) |
| Anti-DsDNA positive, n (%) | 16 (30.8%) |
| ESR mm/h | 15.2 (±18.04) |
| C3 g/L | 1.09 (±0.31) |
| C4 g/L | 0.21 (±0.14) |
| SLAM | 5.66 (±2.39) |
| SELENA SLEDAI | 4.46 (±4) |
| BILAG | 6.1 (±6.29) |
| SLICC/ACR | 0.96 (±1.12) |
| Neurological involvement, n (%) | 5 (9.6%) |
| Renal involvement, n (%) | 4 (7.7%) |
| Urine Hg ng/g creatinine | 1.1 (±1.24) |
| Hair Hg ppm | 1.5 (±1.55) |
| Dental amalgams | 4.9 (±4.6) |
Anti-DsDNA antibody: anti double stranded DNA antibody; BILAG: British Isles Lupus Assessment Group index; BMI: Body mass index; C3: Complement 3; C4: Complement 4; ESR: erythrocyte sedimentation rate; Hg: mercury; SELENA SLEDAI: Safety of Estrogen in Lupus Erythematosus National Assessment Systemic Lupus Activity Index; SLAM: Systemic Lupus Activity Measure; SLE: Systemic Lupus Erythematosus; SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.